Publications
Publications resulting from research funded by The Foundation for Metabolic Cancer Therapies.
-
Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma:
Zachary M. Augur, Catherine M. Doyle, Mingyi Li, Purna Mukherjee and Thomas N. Seyfried* Thomas N. Seyfried Laboratory, Biology Department, Boston College, Chestnut Hill, MA, United States -
Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis:
Christos Chinopoulos1 and Thomas N. Seyfried -
Management of Glioblastoma Multiforme in a patient treated With Ketogenic Metabolic therapy and Modified standard of Care: a 24-Month Follow-Up:
Ahmed M. A. Elsakka1, Mohamed Abdel Bary2, Eman Abdelzaher 3, Mostafa Elnaggar 4, Miriam Kalamian5, Purna Mukherjee6 and Thomas N. Seyfried6* -
Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer:
Mehmet Salih İyikesici , Abdul Kadir Slocum , Ayshe Slocum , Ferhan Bulent Berkarda , Miriam Kalamian , Thomas N. Seyfried -
Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma:
Purna Mukherjee1, Zachary M. Augur1, Mingyi Li1, Collin Hill2, Bennett Greenwood2, Marek A. Domin3, Gramoz Kondakci2, Niven R. Narain2, Michael A. Kiebish2, Roderick T. Bronson4, Gabriel Arismendi-Morillo5, Christos Chinopoulos 6 & Thomas N. Seyfried1 -
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?:
Thomas N. Seyfried1 · Laura Shelton2 · Gabriel Arismendi‑Morillo3 · Miriam Kalamian4 · Ahmed Elsakka5 · Joseph Maroon6 · Purna Mukherjee1No major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The currentNo major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The currentstandard of care (SOC) for GBM involves immediate surgical resection followed by radiotherapy with concomitanttemozolomide chemotherapy. Corticosteroid (dexamethasone) is often prescribed to GBM patients to reduce tumor edemaand inflammation. The SOC disrupts the glutamate–glutamine cycle thus increasing availability of glucose and glutaminein the tumor microenvironment. Glucose and glutamine are the prime fermentable fuels that underlie therapy resistance anddrive GBM growth through substrate level phosphorylation in the cytoplasm and the mitochondria, respectively.